# Lymphocyte Depletion and Stem Cell Transplantation to Treat Severe Systemic Lupus Erythematosus

> **NCT00076752** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 9 (actual)

## Conditions studied

- Lupus Erythematosus, Systemic

## Interventions

- **DRUG:** fludarabine phosphate
- **DRUG:** cyclophosphamide
- **BIOLOGICAL:** Rituxan (rituximab)
- **BIOLOGICAL:** filgrastim
- **DRUG:** methylprednisolone
- **OTHER:** immunologic technique
- **OTHER:** laboratory biomarker analysis
- **PROCEDURE:** autologous hematopoietic stem cell transplantation
- **DRUG:** Diphenhydramine
- **DRUG:** Mesna

## Key facts

- **NCT ID:** NCT00076752
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-01-30
- **Primary completion:** 2013-10-15
- **Final completion:** 2013-10-15
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2021-01-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00076752

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00076752, "Lymphocyte Depletion and Stem Cell Transplantation to Treat Severe Systemic Lupus Erythematosus". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00076752. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*